宏源药业
(301246)
| 流通市值：43.02亿 | | | 总市值：107.52亿 |
| 流通股本：1.60亿 | | | 总股本：4.00亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,317,076,113.48 | 882,558,988.14 | 433,455,447.87 | 1,770,723,711.98 |
| 营业收入 | 1,317,076,113.48 | 882,558,988.14 | 433,455,447.87 | 1,770,723,711.98 |
| 二、营业总成本 | 1,292,835,287.81 | 865,650,935.27 | 416,830,661.03 | 1,712,679,177.05 |
| 营业成本 | 1,149,650,892.3 | 767,049,606.04 | 376,585,908.33 | 1,554,957,164.84 |
| 税金及附加 | 9,121,199.39 | 6,034,293.09 | 3,319,570.38 | 10,127,284.25 |
| 销售费用 | 33,164,828.15 | 21,924,338.62 | 8,092,985.15 | 37,331,641.46 |
| 管理费用 | 38,703,192.73 | 27,945,888.46 | 12,614,316.94 | 54,053,147.73 |
| 研发费用 | 55,846,719.9 | 39,589,553.45 | 16,336,047.27 | 59,177,990.33 |
| 财务费用 | 6,348,455.34 | 3,107,255.61 | -118,167.04 | -2,968,051.56 |
| 其中:利息费用 | 6,880,196.05 | 6,880,196.05 | 3,070,471.12 | 11,999,930.57 |
| 其中:利息收入 | 3,897,184.37 | 3,897,184.37 | 2,850,803.38 | 11,071,461.32 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,832,003.54 | 812,583.52 | 3,748,778.09 | 3,817,511.65 |
| 加:投资收益 | -1,521,506.2 | 63,026.25 | -1,756,535.48 | 3,052,812.1 |
| 资产处置收益 | 723,042.49 | 67,192.75 | 58,294.69 | 533,612.43 |
| 资产减值损失(新) | -28,988,134.13 | -23,976,610.81 | -10,596,812.38 | -34,813,418.11 |
| 信用减值损失(新) | -2,637,648.45 | -2,077,677.6 | -1,097,218.04 | -1,620,390.8 |
| 其他收益 | 12,955,100.55 | 8,251,398.99 | 5,274,788.81 | 31,029,964.4 |
| 四、营业利润 | 6,603,683.47 | 47,965.97 | 12,256,082.53 | 60,044,626.6 |
| 加:营业外收入 | 194,975.99 | 84,654.36 | 66,650.74 | 128,926.99 |
| 减:营业外支出 | 1,602,380.06 | 935,706.71 | 573,259.4 | 482,678.11 |
| 五、利润总额 | 5,196,279.4 | -803,086.38 | 11,749,473.87 | 59,690,875.48 |
| 减:所得税费用 | 7,140,272.44 | 5,605,184.84 | 2,926,078.94 | 8,229,119.75 |
| 六、净利润 | -1,943,993.04 | -6,408,271.22 | 8,823,394.93 | 51,461,755.73 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -1,943,993.04 | -6,408,271.22 | 8,823,394.93 | 51,461,755.73 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -1,100,159.67 | -5,810,427.95 | 8,886,072.24 | 51,465,054.11 |
| 少数股东损益 | -843,833.37 | -597,843.27 | -62,677.31 | -3,298.38 |
| 扣除非经常损益后的净利润 | -24,400,092.83 | -21,591,317 | 712,743.32 | 9,296,887.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | -0.01 | 0.02 | 0.13 |
| (二)稀释每股收益 | 0 | -0.01 | 0.02 | 0.13 |
| 九、综合收益总额 | -1,943,993.04 | -6,408,271.22 | 8,823,394.93 | 51,461,755.73 |
| 归属于母公司股东的综合收益总额 | -1,100,159.67 | -5,810,427.95 | 8,886,072.24 | 51,465,054.11 |
| 归属于少数股东的综合收益总额 | -843,833.37 | -597,843.27 | -62,677.31 | -3,298.38 |
| 公告日期 | 2025-10-23 | 2025-08-28 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |